A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Determine the Safety and Efficacy of AMG 827 in Subjects With Inadequately Controlled Asthma
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Encinitas、California、アメリカ
- Research Site
-
Huntington Beach、California、アメリカ
- Research Site
-
Los Angeles、California、アメリカ
- Research Site
-
San Diego、California、アメリカ
- Research Site
-
Stockton、California、アメリカ
- Research Site
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ
- Research Site
-
-
Georgia
-
Stockbridge、Georgia、アメリカ
- Research Site
-
-
Maryland
-
Baltimore、Maryland、アメリカ
- Research Site
-
-
Massachusetts
-
North Dartmouth、Massachusetts、アメリカ
- Research Site
-
-
Missouri
-
Saint Louis、Missouri、アメリカ
- Research Site
-
-
Montana
-
Bozeman、Montana、アメリカ
- Research Site
-
-
Nebraska
-
Bellevue、Nebraska、アメリカ
- Research Site
-
-
New Jersey
-
Skillman、New Jersey、アメリカ
- Research Site
-
-
New York
-
Rockville Centre、New York、アメリカ
- Research Site
-
-
North Carolina
-
High Point、North Carolina、アメリカ
- Research Site
-
-
Ohio
-
Cincinnati、Ohio、アメリカ
- Research Site
-
-
Oregon
-
Lake Oswego、Oregon、アメリカ
- Research Site
-
Medford、Oregon、アメリカ
- Research Site
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ
- Research Site
-
-
Texas
-
Dallas、Texas、アメリカ
- Research Site
-
El Paso、Texas、アメリカ
- Research Site
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ
- Research Site
-
-
-
-
-
Rotterdam、オランダ
- Research Site
-
-
-
-
-
Feldbach、オーストリア
- Research Site
-
Hallein、オーストリア
- Research Site
-
Wien、オーストリア
- Research Site
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ
- Research Site
-
-
Ontario
-
Ottawa、Ontario、カナダ
- Research Site
-
Toronto、Ontario、カナダ
- Research Site
-
-
-
-
-
Edeleny、ハンガリー
- Research Site
-
Matrahaza、ハンガリー
- Research Site
-
Tatabanya、ハンガリー
- Research Site
-
Torokbalint、ハンガリー
- Research Site
-
Zalaegerszeg - Pozva、ハンガリー
- Research Site
-
-
-
-
-
Helsinki、フィンランド
- Research Site
-
Jyväskylä、フィンランド
- Research Site
-
Turku、フィンランド
- Research Site
-
-
-
-
-
Bruxelles、ベルギー
- Research Site
-
Leuven、ベルギー
- Research Site
-
Liege、ベルギー
- Research Site
-
-
-
-
-
Bialystok、ポーランド
- Research Site
-
Chodziez、ポーランド
- Research Site
-
Gdansk、ポーランド
- Research Site
-
Wroclaw、ポーランド
- Research Site
-
-
-
-
-
Moscow、ロシア連邦
- Research Site
-
Saint Petersburg、ロシア連邦
- Research Site
-
-
-
-
-
Bucheon-si、大韓民国
- Research Site
-
Seoul、大韓民国
- Research Site
-
Suwon、大韓民国
- Research Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Men or women 18 to 65 years of age
- Percent of predicted FEV1 ≥ 50% and ≤ 80%
- At least 12% reversibility over pre-bronchodilator FEV1
- Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000 µg/day fluticasone powder or equivalent
- Ongoing asthma symptoms with ACQ composite score ≥ 1.5 points
Exclusion Criteria:
- Respiratory infection within 4 weeks of screening visit or 1 week of baseline visit
- History of chronic obstructive pulmonary disease or other chronic pulmonary condition other than asthma
- Any uncontrolled or clinically significant systemic disease (eg, uncontrolled diabetes, liver disease)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:Placebo
Participants will receive the matching placebo administered as subcutaneous (SC) injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
実験的:AMG 827 140 mg
Participants will receive AMG 140 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
実験的:AMG 827 210 mg
Participants will receive AMG 210 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
実験的:AMG 827 280 mg
Participants will receive AMG 280 mg administered as SC injections at Day 1 and weeks 1, 2, 4, 6, 8, and 10.
|
SC injection.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores to Week 12
時間枠:Baseline and Week 12
|
The ACQ is an instrument used in clinical research and practice to evaluate asthma control/impairment. It is a validated composite score that assesses disease control by evaluating 7 questions: night time awakenings, asthma symptoms upon awakening, activity limitation, shortness of breath, wheeze frequency, short-acting bronchodilator use, and forced expiratory volume in 1 second (FEV1). The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/limitation) scale. The total score is obtained by adding the value from each question and dividing by the number of questions. Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Change From Baseline in Pre- and Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
時間枠:Baseline and Week 12
|
FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.
FEV1 was performed both pre and post-administration of bronchodilator treatment at Baseline and Week 12.
|
Baseline and Week 12
|
Change From Baseline in AM and PM Peak Expiratory Flow Rate (PEFR) to Week 12
時間枠:Baseline and Week 12
|
Baseline and Week 12
|
|
Change From Baseline in the Frequency of Rescue Short Acting β-Agonist (SABA) Use to Week 12
時間枠:Baseline to Week 12
|
Participants recorded SABA use for 1 week prior to randomization (baseline) and the average number of days recorded was subtracted from average days of SABA use across 12 week intervention period.
|
Baseline to Week 12
|
Change From Baseline in Daily Asthma Symptom Score to Week 12
時間枠:Baseline and Week 12
|
Participants recorded their daily asthma symptoms in their electronic diaries (Ediary). It included 7 questions: frequency of night time awakening, time awake at night, wheezing, shortness of breath, cough, chest tightness and activity limitation. Daily asthma symptoms score is the sum of 7 individual scores (with the total score ranging from 0-21). Higher scores indicates worsening of condition and a negative change from baseline indicates improvement. |
Baseline and Week 12
|
Change From Baseline in Asthma Quality of Life Questionnaire (AQLQ) Score at Week 12
時間枠:Baseline and Week 12
|
The AQLQ is the most commonly used asthma specific instrument and includes evaluations of both symptom and quality of life measures. The 32-item instrument measures 4 domains affected by asthma including activity limitations, emotional function, exposure to environmental stimuli, and symptoms (Mitchell EA et al, 1997, Juniper et al, 1994, Christie MJ et al, 1993, Juniper et al, 1993). Participants were asked to recall their experiences during the last 2 weeks and to respond to each question on a 7-point scale (7=no impairment, 1=severe impairment). The overall score = mean of the responses to the 32 questions. Higher scores indicate "better quality of life" and a positive change from baseline indicates improved symptoms. |
Baseline and Week 12
|
Proportion of Asthma Symptom-free Days
時間枠:Up to Week 12
|
Asthma symptom-free days were defined as a participant having a score of zero in their daily asthma symptom score. Asthma symptom-free days without SABA use were defined as a participant having a score of zero in their daily asthma symptom score and no SABA use. The proportion of asthma symptom-free days was calculated as the number of asthma symptom-free days over the number of days in the double-blind treatment period (12 weeks). |
Up to Week 12
|
Time to Maximum Observed Concentration (Tmax) of AMG 827 at Week 8 to 10
時間枠:Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
Maximum Observed Concentration (Cmax) of AMG 827 at Week 8 to 10
時間枠:Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
|
Area Under the Concentration-time Curve During the Dosing Interval (AUCtau) of AMG 827 at Week 8 to 10
時間枠:Week 8 (days 60 and 64), and pre-dose on Week 10
|
Week 8 (days 60 and 64), and pre-dose on Week 10
|
協力者と研究者
スポンサー
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
Placeboの臨床試験
-
Palacky University完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
University Hospital, Strasbourg, France積極的、募集していない